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Background
BAY 58-2667 (cinaciguat) directly activates soluble guan-
ylyl cyclase without tolerance in a NO-independent man-
ner, and its hemodynamic effect is similar to that of
nitroglycerin. We tested whether BAY 58-2667 could
make both rabbit and rat hearts resistant to infarction
when given at the end of an ischemic insult.
Methods and results
All hearts were exposed to 30-min regional ischemia fol-
lowed by 120-(isolated hearts) or 180-(in situ hearts) min
reperfusion. BAY 58-2667 (1–50 nM) infused for 60-min
starting 5-min before reperfusion significantly reduced
infarction from 33.0 ± 3.2% in control isolated rabbit
hearts to 9.5–12.7% (p < 0.05). In a more clinically rele-
vant in situ rabbit model infarct size was similarly reduced
with a loading dose of 53.6 μg/kg followed by a 60-min
infusion of 1.25 μg/kg/min (41.1 ± 3.1% infarction in
control hearts to 16.0( ±)4.4% in treated hearts, p < 0.05).
BAY 58-2667 similarly decreased infarction in the isolated
rat heart, and protection was abolished by co-treatment
with a protein kinase G (PKG) antagonist, or a mitochon-
drial KATP  channel antagonist. Conversely, Nω-nitro-L-
arginine-methyl-ester-hydrochloride, a NO-synthase
inhibitor, failed to block BAY 58-2667's ability to decrease
infarction, consistent with the latter's putative NO-inde-
pendent activation of PKG. Finally, BAY 58-2667
increased myocardial cGMP content in reperfused hearts
while cAMP was unchanged.
Conclusion
When applied at reperfusion BAY 58-2667 is an effective
cardioprotective agent with a mechanism similar to that
of ischemic preconditioning and, hence, should be a can-
didate for treatment of acute myocardial infarction in
man.
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